Nitric oxide and cancer: a review

Sheetal Korde Choudhari, Minal Chaudhary, Sachin Bagde, Amol R Gadbail, Vaishali Joshi, Sheetal Korde Choudhari, Minal Chaudhary, Sachin Bagde, Amol R Gadbail, Vaishali Joshi

Abstract

Nitric oxide (NO), is a ubiquitous, water soluble, free radical gas, which plays key role in various physiological as well as pathological processes. Over past decades, NO has emerged as a molecule of interest in carcinogenesis and tumor growth progression. However, there is considerable controversy and confusion in understanding its role in cancer biology. It is said to have both tumoricidal as well as tumor promoting effects which depend on its timing, location, and concentration. NO has been suggested to modulate different cancer-related events including angiogenesis, apoptosis, cell cycle, invasion, and metastasis. On the other hand, it is also emerging as a potential anti-oncogenic agent. Strategies for manipulating in vivo production and exogenous delivery of this molecule for therapeutic gain are being investigated. However, further validation and experimental/clinical trials are required for development of novel strategies based on NO for cancer treatment and prevention. This review discusses the range of actions of NO in cancer by performing an online MEDLINE search using relevant search terms and a review of the literature. Various mechanisms by which NO acts in different cancers such as breast, cervical, gastric,colorectal, and head and neck cancers are addressed. It also offers an insight into the dichotomous nature of NO and discusses its novel therapeutic applications for cancer prevention and treatment.

Figures

Figure 1
Figure 1
Potential roles of NO in tumor growth.

References

    1. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987;11:9265–9269.
    1. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelial-derived relaxing factor. Nature. 1987;11:524–526.
    1. Thomson LL, Lawton FG, Knowles RG, Basley JE, Riversomoreno V, Moncada S. NO synthase activity in human gynecological cancer. Cancer Res. 1994;11:1352–1354.
    1. Taysi S, Uslu C, Akcay F, Sutbeyaz MY. MDA and nitric oxide in the plasma of patients with advanced laryngeal cancer. Surg Today. 2003;11(9):651–654.
    1. Cabs CS, Brenman JE, Aldape KD, Bredt DS, Isrnael MA. Expression of NOS in human central nervous system tumors. Cancer Res. 1995;11:727–730.
    1. Reveneau S, Arnould L, Jolimoy G, Hilpert S, Lejeune P, Saint-Giorgio V, Belichard C, Jeannin JF. Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptor. Lab Invest. 1999;11:1215–1225.
    1. Prazma J, Pertrusz P, Mims W, Ball SS, Weissler MC. Immunohistochemical characterization of NOS activity in squamous cell carcinoma of head and neck. Otolaryngol Head Neck Surg. 1995;11:541–549.
    1. Ying L, Hofseth LJ. An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res. 2007;11:1407–1410.
    1. Shang ZJ, Li JR, Li ZB. Effects of exogenous nitric oxide on oral squamous cell carcinoma: an in vitro study. J Oral Maxillofac Surg. 2002;11(8):905–910.
    1. Harada K, Supriatno, Kawaguchi S, Tomitaro O, Yoshida H, Sato M. Overexpression of iNOS gene suppresses the tumorigenicity and metastasis of oral cancer cells. In Vivo. 2004;11(4):449–455.
    1. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathology, and pharmacology. Pharmacol Rev. 1991;11:109–142.
    1. Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP, Tzeng EE, Geller DA, Billiar TR, Harris CC. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med. 1998;11:1371–1376.
    1. Grisham MB, Jourd’heuil D, Wink DA. Nitric oxide: I.Physiological chemistry of nitric oxide and its metabolites: implications in inflammation. Gastrointest Liver Physiolo1. 1999;11:315–321.
    1. Kanner J, Harel S, Granit R. Nitric oxide as an antioxidant. Arch Biochem Biophys. 1991;11(1):130–136.
    1. Subapriya R, Kumaraguruparan R, Ramachandran CR, Nagini S. Oxidant-antioxidant status in patients with oral squamous cell carcinomas at different intraoral sites. Clin Biochem. 2002;11:489–493.
    1. Tamir S, Tannenbaum SR. The role of nitric oxide (NO) in the carcinogenic process. Biochim Biophys Acta. 1996;11:F31–F36.
    1. Wink DA, Mitchell JB. The chemical biology of NO. Insights into regulation, protective and toxic mechanisms of nitric oxide. Free Radic Biol Med. 1998;11(4/5):434–456.
    1. Patel RP, McAndrew J, Sellak H, White RC, Jo H, Freeman BA, Darley-Usmar VM. Biological aspects of reactive nitrogen species. Biochim Biophys Acta. 1999;11:385–400.
    1. de Rojas-Walker T, Tamir S, Ji H, Wishnok JS, Tannenbaum SR. Nitric oxide induces oxidative damage in addition to deamination in macrophage DNA. Chem Res Toxicol. 1995;11:473–477.
    1. Gal A, Wogan GN. Mutagenesis associated with nitric oxide production in transgenic SJL mice. Proc Natl Acad Sci USA. 1996;11:15102–15107.
    1. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis. 1998;11(5):711–721.
    1. Sun Y. Free radicals, antioxidant enzymes and carcinogenesis. Free Radic Biol Med. 1990;11:583–599.
    1. Wink DA, Kasprzak KS, Maragos CM, Elespuru RK, Misra M, Dunams TM, Cebula TA, Koch WH, Andrews AW, Allen JS. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science. 1992;11:1001–1003.
    1. Choi BM, Pae HO, Jang SI, Kim YM, Chung HT. Nitric oxide as a pro-apoptotic as well as anti-apoptotic modulator. J Biochem Mol Biol. 2002;11:116–126.
    1. Von KA, Brune B. Cyclooxygenase-2: an essential regulator of NO-mediated apoptosis. FASEBJ. 1997;11:887–895.
    1. Ziche M, Morbidelli L. Nitric oxide and angiogenesis. J Neurooncol. 2000;11:139–148.
    1. Lala PK, Orucevic A. Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev. 1998;11:91–106.
    1. Breast Cancer Awareness Month in October (World Health Organization 2012)
    1. Loibl S, von Minckwitz G, Weber S, Sinn HP, Schini-Kerth VB, Lobysheva I, Nepveu F, Wolf G, Strebhardt K, Kaufmann M. Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy. Cancer. 2002;11(6):1191–1198.
    1. Alagol H, Erdem E, Sancak B, Turkmen G, Camlibel M, Bugdayci G. Nitric oxide biosynthesis and malondialdehyde levels in advanced breast cancer. Aust N Z J Surg. 1999;11(9):647–650.
    1. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer. 1995;11(1):41–44.
    1. Jadeski LC, Hum KO, Chakraborty C, Lala PK. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer. 2000;11:30–39.
    1. Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakashara M, Nakao K, Nakamura M, Kakudo K. NO in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res. 2006;11(4):1201–1207.
    1. Switzer CH, Cheng RY-S, Ridnour LA, Glynn SA, Ambs S, Wink DA. Ets-1 is a transcriptional mediator of oncogenic nitric oxide signalling in estrogen receptor negative breast cancer. Breast Cancer Res. 2012;11:R125.
    1. Tschugguel W, Knogler W, Czerwenka K, Mildner M, Weninger W, Zeillinger R, Huber JC. Presence of endothelial calcium-dependent nitric oxide synthase in breast apocrine metaplasia. Br J Cancer. 1996;11:1423–1426.
    1. Zeillinger R, Tantscher E, Schneeberger C, Tschugguel W, Eder S, Sliutz G, Huber JC. Simultaneous expression of nitric oxide synthase and estrogen receptor in human breast cancer cell lines. Breast Cancer Res Treat. 1996;11(2):205–207.
    1. Pance A. Nitric oxide hormones and breast cancer. Nitric oxide and hormones in breast cancer: allies or enemies? Future Oncol. 2006;11(2):275–288.
    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin. 2005;11:74–108.
    1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;11:342–350.
    1. Benencia F, Gamba G, Cavalieri H, Courreges MC, Benedetti R, Villamil SM, Massouh EJ. Nitric oxide and HSV vaginal infection in BALB/c mice. Virology. 2003;11:75–84.
    1. Carratelli CR, Rizzo A, Paolillo R, Catania MR, Catalanotti P, Rossano F. Effect of nitric oxide on the growth of Chlamydophilapneumoniae. Can J Microbiol. 2005;11(11):941–947.
    1. Chang K, Lubo Z. Review article: steroid hormones and uterine vascular adaptation to pregnancy. Reprod Sci. 2008;11:336–348.
    1. Naidu MSK, Suryakar AN, Swami SC, Katkam RV, Kumbar KM. Oxidative stress and antioxidant status in cervical cancer patients. Indian J Clin Biochem. 2007;11(2):140–144.
    1. Beevi SS, Rasheed MH, Geetha A. Evidence of oxidative and nitrosative stress in patients with cervical squamous cell carcinoma. Clinica Chimica Acta. 2007;11(1–2):119–123.
    1. Hiraku Y, Tabata T, Ma N, Murata M, Ding X, Kawanishi S. Nitrative and oxidative DNA damage in cervical intraepithelial neoplasia associated with human papilloma virus infection. Cancer Sci. 2007;11:964–972.
    1. Tavares-Murta BM, de Resende AD, Cunha FQ, Murta EFC. Local profile of cytokines and nitric oxide in patients with bacterial vaginosis and cervical intraepithelial neoplasia. Eur J Obstet Gynecol Repro Biol. 2008;11:93–99.
    1. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;11:12–19.
    1. Wei L, Gravitt PE, Song H, Maldonado AM, Ozbun MA. Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human papillomavirus-infected cells. Cancer Res. 2009;11:4878–4884.
    1. Wei XM, Wang Q, Gao SJ, Sui L. Relationship between nitric oxide in cervical microenvironment and different HPV types and effect on cervical cancer cells. Zhonghua Fu Chan Ke Za Zhi. 2011;11(4):260–265.
    1. Mulshine JL, Frank C, Melvyn S, De Luca LM. Lung cancer evolution to preinvasive management. Clin Chest Med. 2002;11(1):1–25.
    1. Bilello KS, Murin S, Matthay RA. Epidemiology, etiology, and prevention of lung cancer. Clin Chest Med. 2002;11(1):1–25.
    1. Masri FA, Comhair SAA, Koeck T, Xu W, Janocha A, Ghosh S, Dweik RA, Golish J, Kinter M, Stuehr DJ, Erzurum SC, Aulak KS. Abnormalities in nitric oxide and its derivatives in lung cancer. Am J Respir Crit Care Med. 2005;11:597–605.
    1. Chen GG, Lee TW, Xu H, Yip JH, Li M, Mok TS, Yim AP. Increased inducible nitric oxide synthase in lung carcinoma of smokers. Cancer. 2008;11(2):372–381.
    1. Puhakka AR, Harju TH, Paakko PK, Soini YM, Kinnula VL. Nitric oxide synthases are associated with bronchial dysplasia. Lung Cancer. 2006;11(3):275–282.
    1. Forbes TA, Hopkins L, Schneider B, Lazarus L, Leitenberg D, Constant S, Schwartz A, Patierno S, Ceryak S. Potential role of nitric oxide in chromium-induced lung carcinogenesis. Cancer Res. 2012;11(8 Suppl):5456. Abstract.
    1. Beckman JS, Ischiropoulos H, Zhu L, van der Woerd M, Smith C, Chen J, Harrison J, Martin JC, Tsai M. Kinetics of superoxide dismutaseand iron-catalyzed nitration of phenolics by peroxynitrite. Arch Biochem Biophys. 1992;11:438–445.
    1. Haddad IY, Pataki G, Hu P, Galliani C, Beckman JS, Matalon S. Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury. J Clin Invest. 1994;11:2407–2413.
    1. MacMillan-Crow LA, Crow JP, Kerby JD, Beckman JS, Thompson JA. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA. 1996;11:11853–11858.
    1. Cobbs CS, Whisenhunt TR, Wesemann DR, Harkins LE, Erwin G, Van M, Minu S. Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant gliomacells. Cancer Res. 2003;11:8670–8673.
    1. Masri F. Role of nitric oxide and its metabolites as potential markers in lung cancer. Ann Thorac Med. 2010;11(3):123–127.
    1. Correa P, Piazuelo MB, Camargo MC. The future of gastric cancer prevention. Gastric Cancer. 2004;11(1):9–16.
    1. Calatayud S, Barrachina D, Esplugues JV. Nitric oxide: relation to integrity, injury, and healing of the gastric mucosa. Microsc Res Tech. 2001;11(5):325–335.
    1. Yagihashi N, Kasajima H, Sugai S, Matsumoto K, Ebina Y, Morita T, Murakami T, Yagihashi S. Increased in situ expression of nitric oxide synthase in human colorectal cancer. Virchows Arch. 2001;11(2):109–114.
    1. Feng CW, Wang LD, Jiao LH, Liu B, Zheng S, Xie XJ. Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features. BMC Cancer. 2002;11:8. 1–7.
    1. Correa P. Human gastric carcinogenesis. A multistep and multifactorial process–first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;11:6735–6740.
    1. You WC, Blot WJ, Li JY, Chang YS, Jin ML, Kneller R, Zhang L, Han ZX, Zeng XR, Liu WD, Zhao L, Correa P, Fraumeni JF, Xu GW. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res. 1993;11:1317–1321.
    1. Nardone G. Review article: Molecular basis of gastric carcinogenesis. Aliment Pharmacol Ther. 2003;11(Suppl. 2):75–81.
    1. Parsonnet J, Friedman GD, Oremtreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut. 1997;11:297–301.
    1. Nomura A, Stemmermann GN, Chyou PH, Kato J, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;11:1132–1136.
    1. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterol. 1998;11(3):642–648.
    1. Honda S, Fujioka T, Tokieda M, Satoh R, Nishizono A, Nasu M. Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res. 1998;11:4255–4259.
    1. Nam KT, Oh SY, Ahn B, Kim YB, Jang DD, Yang KH, Hahm KB, Kim DY. Decreased Helicobacter pylori associated gastric carcinogenesis in mice lacking inducible nitric oxide synthase. Gut. 2004;11(9):1250–1255.
    1. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: areview. Human Mutat. 2003;11:258–270.
    1. Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannebaum SR. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA. 1992;11:3030–3034.
    1. Broholm H, Rubin I, Kruse A, Braendstrup O, Schmidt K, Skriver EB, Lauritzen M. Nitric oxide synthase expression and enzymatic activity in human brain tumors. Clin Neuropathol. 2003;11(6):273–281.
    1. Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 1995;11:727–730.
    1. Nagpal JK, Das BR. Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management. Oral Oncol. 2003;11:213–221.
    1. Patel BP, Rawal UM, Rawal RM, Shukla SN, Patel PS. Tobacco, antioxidant enzymes, oxidative stress, and genetic susceptibility in oral cancer. Am J Clin Oncol. 2008;11(5):454–459.
    1. Nair U, Bartsch H, Nair J. Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms. Mutagenesis. 2004;11(4):251–262.
    1. Rasheed MH, Beevi SS, Geetha A. Enhanced lipid peroxidation and nitric oxide products with deranged antioxidant status in patients with head and neck squamous cell carcinoma. Oral Oncol. 2007;11:333–338.
    1. Patel JB, Shah FD, Shukla SN, Shah PM, Patel PS. Role of nitric oxide and antioxidant enzymes in the pathogenesis of oral cancer. JCRT. 2009;11:247–253.
    1. Korde SD, Basak A, Chaudhary M, Goyal M, Vagga A. Enhanced nitrosative and oxidative stress with decreased total antioxidant capacity in patients with oral precancer and oral squamous cell carcinoma. Oncology. 2011;11(5–6):382–389.
    1. Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, Fernandez L, Wünsch-Filho V, Franceschi S, Hayes RB, Herrero R, Koifman S, La Vecchia C, Lazarus P, Levi F, Mates D, Matos E, Menezes A, Muscat J, Eluf-Neto J, Olshan AF, Rudnai P, Schwartz SM, Smith E, Sturgis EM, Szeszenia-Dabrowska N, Talamini R. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst. 2007;11(10):777–789.
    1. Cooper RG, Magwere T. Nitric oxide-mediated pathogenesis during nicotine and alcohol consumption. Indian J Physiol Pharmacol. 2008;11(1):11–18.
    1. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;11(9):709–720.
    1. Pintos J, Black MJ, Sadeghi N, Ghadirian P, Zeitouni AG, Viscidi RP, Herrero R, Coutlée F, Franco EL. Human papillomavirus infection and oral cancer: a case–control study in Montreal. Canada. Oral Oncol. 2008;11(3):242–250.
    1. D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML. Case–control study of human papillomavirus and oropharyngeal cancer. New Engl J Med. 2007;11(19):1944–1956.
    1. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against highgradevulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;11(9574):1693–1702.
    1. Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D'Souza G, Gravitt PE, Westra W, Psyrri A, Kast WM, Koutsky LA, Giuliano A, Krosnick S, Trotti A, Schuller DE, Forastiere A, Ullmann CD. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C. Head Neck. 2009;11(11):1393–1422.
    1. Li LM, Kibourn RG, Adams J, Filder IJ. Role of NO in lysis of tumor cells by cytokine activated endothelial cells. Cancer Res. 1991;11:2531–2535.
    1. Shang ZJ, Li JR. Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in oral squamous cell carcinoma: its correlation with angiogenesis and disease progression. J Oral Pathol Med. 2005;11:134–139.
    1. Lechner M, Lirk P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol. 2005;11:277–289.
    1. Lepoivre M, Flaman JM, Henry Y. Early loss of the tyrosyl radical in ribonucleotidereductase of adenocarcinoma cells producing nitric oxide. J Biol Chem. 1992;11:22994–23000.
    1. Aranda E, López-Pedrera C, De La Haba-Rodríguez JR, Rodríguez-Ariza A. Nitric oxide and cancer: the emerging role of S nitrosylation. Curr Mol Med. 2012;11:50–67.
    1. Baritaki S, Huerta-Yepez S, Sahakyan A, Karagiannides I, Bakirtzi K, Jazirehi A, Bonavida B. Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP. Cell Cycle. 2010;11:4931–4940.
    1. Bonavida B. Inhibition of epithelial-to-mesenchymal transition (EMT) in cancer by nitric oxide: pivotal roles of nitrosylation of NF-κB, YY1 and Snail. For Immunopathol Dis Therap. 2012;11(2):125–133.
    1. Zhao SF, Tong XY, Zhu FD. Nitric oxide induces oral squamous cell carcinoma cells apoptosis with p53 accumulation. Oral Oncol. 2005;11(8):785–790.
    1. Brennan PA, Palacios-Callender M, Umar T, Tant S, Langdon JD. Expression of type 2 nitric oxide synthase and p21 in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2002;11(2):200–205.
    1. Gallo O, Emanuela M, Lucia M, Franchi A, Fini-storchi I, Vergari WA, Ziche M. Role of NO in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst. 1998;11:587–596.
    1. Korde(Choudhari) S, Sridharan G, Gadbail A, Poornima V. Nitric oxide and oral cancer: A review. Oral Oncol. 2012;11:475–483.
    1. Singh S, Gupta AK. Mini review nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother Pharmacol. 2011;11(6):1211–1224.
    1. Lehrman S. Virus treatment questioned after gene therapy death. Nature. 1991;11:517–518.
    1. Huerta S, Chilka S, Bonavida B. Nitric oxide donors: novel cancer therapeutics (Review) Int J Oncol. 2008;11:909–927.
    1. Bonavida B, Baritaki S, Huerta-Yepez S, Vega MI, Chatterjee D, Yeung K. Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases. Nitric oxide. 2008;11(2):152–157.
    1. Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A, Asada M, Inoue D, Suzuki T, Okazaki T, Takahashi H, Yoshida M, Kaneta T, Ishizawa K, Yamanda S, Tomita N, Yamasaki M, Kikuchi A, Kubo H, Sasaki H. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2006;11:688–694.
    1. Yasuda H, Nakayama K, Watanabe M, Suzuki S, Fuji H, Okinaga S, Kanda A, Zayasu K, Sasaki T, Asada M, Suzuki T, Yoshida M, Yamanda S, Inoue D, Kaneta T, Kondo T, Takai Y, Sasaki H, Yanagihara K, Yamaya M. Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin Cancer Res. 2006;11:6748–6757.
    1. Bonavida B, Baritaki S. Dual role of NO donors in the reversal of tumor cell resistance and EMT: downregulation of the NF-jB/Snail/YY1/RKIP circuitry. Nitric Oxide. 2011;11(1):1–7.
    1. Lee DH, Pfeifer GP. Mutagenesis induced by the nitric oxide donor sodium nitroprusside in mouse cells. Mutagenesis. 2007;11:63–67.
    1. Rigas B. Novel agents for cancer prevention based on nitric oxide. Biochem Soc Trans. 2007;11:136–138.
    1. Frost MC, Reynolds MM, Meyerhoff ME. Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contacting medical devices. Biomaterials. 2005;11(14):1685–1693.
    1. Seabra AB, Duran N. Nitric oxide-releasing vehicles for biomedical applications. J Mater Chem. 2010;11(9):1624–1637.
    1. Saraiva J, Marotta-Oliveira SS, Cicillini SA, de Oliveira Eloy J, Marchett JM. Nanocarriers for nitric oxide delivery. J Drug Deliv. 2011;11:1–16.
    1. Quintanar-Guerrero D, Ganem-Quintanar A, Allemann E, Fessi H, Doelker E. Influence of the stabilizer coating layer on the purification and freeze-drying of poly(D, Llactic acid) nanoparticles prepared by an emulsion-diffusion technique. J Microencapsul. 1998;11(1):107–119.
    1. Jain R, Shah NH, Malick AW, Rhodes CT. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug DevInd Pharm. 1998;11(8):703–727.
    1. Kanayama N, Yamaguchi K, Nagasaki Y. PEGylated polymer micelle-based nitric oxide (NO) photodonor with NO-mediated antitumor activity. Chem Lett. 2010;11(9):1008–1009.
    1. Friedman AJ, Han G, Navati MS, Chacko M, Gunther L, Alfieri A, Friedman JM. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide. 2008;11(1):12–20.
    1. Cabrales P, Han G, Roch eC, Nacharaju P, Friedman AJ, Friedman JM. Sustained release nitric oxide from long-lived circulating nanoparticles. Free Radical Bio Med. 2010;11(4):530–538.
    1. Marquele-Oliveira F, Santana DC, Taveira SF, Vermeulen DM, de Oliveira AR, da Silva RS, Lopez RF. Development of nitrosyl ruthenium complex-loaded lipid carriers for topical administration: improvement in skin stability and in nitric oxide release by visible light irradiation. J Pharm Biomed Anal. 2010;11(4):843–851.
    1. Stevens EV, Carpenter AW, Shin JH, Liu J, Der CJ, Schoenfisch MH. Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth. Mol Pharmaceutics. 2010;11(3):775–785.
    1. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science. 1978;11(4374):1290–1293.
    1. Wang J, Teng Y, Hao Y, Oh-Lee J, Mohanty DK. Preparation and properties of polyamines: part IIcontrolled and sustained release of nitric oxide (NO) from nitrosated polymers. Polym J. 2009;11(9):715–725.
    1. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater. 2005;11(6):435–446.
    1. Cicillini SA, Prazias ACL, Tedesco AC, Serra OA, da Silva RS. Nitric oxide and singlet oxygen photo-generation by light irradiation in the phototherapeutic window of a nitrosyl ruthenium conjugated with a phthalocyanine rare earth complex. Polyhedron. 2009;11(13):2766–2770.
    1. Neuman D, Ostrowski AD, Absalonson RO, Strouse GF, Ford PC. Photosensitized NO release from water soluble nanoparticle assemblies. J Am Chem Soc. 2007;11(14):4146–4147.
    1. Hien T, Duong T, Kamarudin ZM, Erlich RB, Li Y, Jones MW, Kavallaris M, Boyer C, Davis TP. Intracellular nitric oxide delivery from stable NO-polymeric nanoparticle carriers. Chem Commun. 2013;11:4190–4192.
    1. Giles NM, Kumari S, Gang BP, Yuen CW, Billaud EM, Giles GI. The molecular design of S-nitrosothiols as photodynamic agents for controlled nitric oxide release. Chem Biol Drug Des. 2012;11(3):471–478.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner